×
About 588 results

ALLMedicine™ Waldenstrom Macroglobulinemia Center

Research & Reviews  273 results

Severe and Irreversible Pancytopenia Associated With SARS-CoV-2 Bone Marrow Infection i...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7832621
Clinical Lymphoma, Myeloma & Leukemia; Velier M, Priet S et. al.

Feb 10th, 2021 - Severe and Irreversible Pancytopenia Associated With SARS-CoV-2 Bone Marrow Infection in a Patient With Waldenstrom Macroglobulinemia.|2021|Velier M,Priet S,Appay R,Atieh T,Lepidi H,|

Multimodal imaging of two cases of retinal vein occlusion secondary to Waldenstrom macr...
https://doi.org/10.1177/1120672121991389
European Journal of Ophthalmology; Remolí Sargues L, Montero Hernández J et. al.

Feb 4th, 2021 - To report multimodal imaging characteristics of two cases of retinal vein occlusion (RVO) secondary to Waldenstrom macroglobulinemia (WM). Case 1: An 82-year-old woman presented with vision loss. She had a history of WM. Best-corrected visual acui...

Bruton Tyrosine Kinase Inhibitors in Waldenstrom Macroglobulinemia: Unprecedented Clini...
https://doi.org/10.1200/JCO.20.02942
Journal of Clinical Oncology : Official Journal of the Am... Owen RG

Jan 14th, 2021 - Bruton Tyrosine Kinase Inhibitors in Waldenstrom Macroglobulinemia: Unprecedented Clinical Activity and Promising Future Directions.|2021|Owen RG,|

Treatment facility volume and patient outcomes in Waldenstrom macroglobulinemia.
https://doi.org/10.1080/10428194.2020.1832669
Leukemia & Lymphoma; Gunaratne MDSK, Sahakian AJ et. al.

Oct 15th, 2020 - Waldenstrom macroglobulinemia (WM) has an annual incidence of 3-3.2 cases per million-person/year. National Cancer Data Base was used to identify newly diagnosed WM cases requiring initiation of therapy and their annual facility volume was used to...

see more →

Guidelines  2 results

Positive Zanubrutinib Data May Spark Change for Treatment of Waldenstrom Macroglobulinemia
https://www.targetedonc.com/view/positive-zanubrutinib-data-may-spark-change-for-treatment-of-waldenstrom-macroglobulinemia

May 28th, 2020 - A higher complete response or very good partial response (CR+VGPR) rate in patients with Waldenström macroglobulinemia (WM) was achieved with Zanubrutinib (Brukinsa), and the drug demonstrated clinically meaningful safety and tolerability, accordi...

Zanubrutinib Shows Efficacy, Tolerability in Waldenstrom Macroglobulinemia
https://www.onclive.com/conference-coverage/asco-2020/zanubrutinib-shows-efficacy-tolerability-in-waldenstrom-macroglobulinemia

May 28th, 2020 - Zanubrutinib (Brukinsa) was associated with a higher complete response or very good partial response (CR+VGPR) rate, as well as clinically meaningful advantages in safety and tolerability, compared with ibrutinib (Imbruvica) in patients with Walde...

see more →

Clinicaltrials.gov  291 results

Severe and Irreversible Pancytopenia Associated With SARS-CoV-2 Bone Marrow Infection i...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7832621
Clinical Lymphoma, Myeloma & Leukemia; Velier M, Priet S et. al.

Feb 10th, 2021 - Severe and Irreversible Pancytopenia Associated With SARS-CoV-2 Bone Marrow Infection in a Patient With Waldenstrom Macroglobulinemia.|2021|Velier M,Priet S,Appay R,Atieh T,Lepidi H,|

Multimodal imaging of two cases of retinal vein occlusion secondary to Waldenstrom macr...
https://doi.org/10.1177/1120672121991389
European Journal of Ophthalmology; Remolí Sargues L, Montero Hernández J et. al.

Feb 4th, 2021 - To report multimodal imaging characteristics of two cases of retinal vein occlusion (RVO) secondary to Waldenstrom macroglobulinemia (WM). Case 1: An 82-year-old woman presented with vision loss. She had a history of WM. Best-corrected visual acui...

Ibrutinib 'Treatment of Choice' in Waldenstrom Macroglobulinemia
https://www.medscape.com/viewarticle/944782

Jan 26th, 2021 - Ibrutinib (Imbruvica) has "become for many clinicians the treatment of choice" for patients with relapsed or refractory Waldenstrom macroglobulinemia (WM). This class of agents (Bruton tyrosine kinase [BTK] inhibitors) represents a "paradigm shift...

Bruton Tyrosine Kinase Inhibitors in Waldenstrom Macroglobulinemia: Unprecedented Clini...
https://doi.org/10.1200/JCO.20.02942
Journal of Clinical Oncology : Official Journal of the Am... Owen RG

Jan 14th, 2021 - Bruton Tyrosine Kinase Inhibitors in Waldenstrom Macroglobulinemia: Unprecedented Clinical Activity and Promising Future Directions.|2021|Owen RG,|

see more →

News  15 results

Ibrutinib 'Treatment of Choice' in Waldenstrom Macroglobulinemia
https://www.medscape.com/viewarticle/944782

Jan 26th, 2021 - Ibrutinib (Imbruvica) has "become for many clinicians the treatment of choice" for patients with relapsed or refractory Waldenstrom macroglobulinemia (WM). This class of agents (Bruton tyrosine kinase [BTK] inhibitors) represents a "paradigm shift...

Positive Zanubrutinib Data May Spark Change for Treatment of Waldenstrom Macroglobulinemia
https://www.targetedonc.com/view/positive-zanubrutinib-data-may-spark-change-for-treatment-of-waldenstrom-macroglobulinemia

May 28th, 2020 - A higher complete response or very good partial response (CR+VGPR) rate in patients with Waldenström macroglobulinemia (WM) was achieved with Zanubrutinib (Brukinsa), and the drug demonstrated clinically meaningful safety and tolerability, accordi...

Zanubrutinib Shows Efficacy, Tolerability in Waldenstrom Macroglobulinemia
https://www.onclive.com/conference-coverage/asco-2020/zanubrutinib-shows-efficacy-tolerability-in-waldenstrom-macroglobulinemia

May 28th, 2020 - Zanubrutinib (Brukinsa) was associated with a higher complete response or very good partial response (CR+VGPR) rate, as well as clinically meaningful advantages in safety and tolerability, compared with ibrutinib (Imbruvica) in patients with Walde...

Change the 'Asymptomatic' Label for Rare Lymphoma Status
https://www.medscape.com/viewarticle/919696

Oct 9th, 2019 - Patients in the early stages of Waldenstrom macroglobulinemia (WM), a rare type of non-Hodgkin lymphoma, are usually followed with observation rather than offered treatment and are labeled "asymptomatic." But this label is inaccurate because many ...

Waldenstrom Macroglobulinemia Clinical Practice Guidelines (2018)
https://reference.medscape.com/viewarticle/905623

Nov 29th, 2018 - The guidelines on the diagnosis, treatment, and follow-up of Waldenstrom macroglobulinemia were released on October 1, 2018, by the European Society for Medical Oncology (ESMO).[1] Diagnosis Waldenstrom macroglobulinemia (WM) is diagnosed based on...

see more →

Patient Education  7 results see all →